Eli Lilly Announces Study Determined Best Dose and Showed 55% Response Rate With Anti-BAFF Monoclonal Antibody in Previously-Treated Multiple Myeloma Patients

Eli Lilly and Company LLY announced Phase I data on LY2127399, a human monoclonal antibody that neutralizes B-cell activating factor, for use in combination with bortezomib in patients with previously-treated multiple myeloma. Results from the Phase I study will be presented on Sunday, June 5 at 11:30 a.m. CDT during the Lymphoma and Plasma Cell Disorders Oral Abstract Session at the 47th Annual Meeting of the American Society of Clinical Oncology in Chicago, Ill.